The number of FDA-approved precision oncology therapies has increased to nearly 100, yet less than 1 in 20 cancer patients receive these treatments.
Acurion is changing that.
OncoGaze™ makes precision therapy relevant for more patients.
By delivering critical genomic insights at the biopsy stage, Acurion’s OncoGaze™ empowers oncologists to make precision therapy a reality for more patients.
OncoGaze™ workflow predicts clinically-actionable genomic biomarkers from routine digital histological tissue slides.
OncoGaze™ uncovers hidden morphological patterns invisible to the human eye – accelerating biomarker screening.
OncoGaze™ provides actionable genomic test results within seconds, rather than months, unlocking life-saving precision therapies when time matters most.
This technology was developed by leading oncologists and some of the most highly cited cancer researchers in the world.
Let's bring precision oncology forward – together.
Explore how Acurion is driving immediate precision for optimal care.
Contact us for a demo of OncoGaze.